Table 5 Demographic, clinical characteristics and laboratory test results at admission and outcome data of the patients with or without decreased cardiac function
Cardiac dysfunction n = 20 (37.7%) | Without cardiac dysfunction n = 33 (62.3%) | p | |
|---|---|---|---|
Demographic and clinical characteristics at admission, n (%) | |||
Age in years, median (min.-max.) | 8 | 6 | 0.003 |
Male sex | 14 (70%) | 18 (54.5%) | 0.265 |
Comorbidities, n (%) | 1 (5%) | 10 (30.3%) | 0.037 |
Fever, days at admission, median | 5.5 | 5 | 0.723 |
Gastrointestinal symptoms | 14 (70%) | 24 (72.8%) | 0.831 |
Diarrhea | 8 (40%) | 5 (15.2%) | 0.042 |
Mucocutaneous symptoms | 17 (85%) | 23 (69.7%) | 0.209 |
Conjunctivitis | 15 (75%) | 15 (45.5) | 0.035 |
Cardiovascular symptoms | 20 (100%) | 10 (30.3%) | < 0.001 |
Respiratory symptoms | 5 (25%) | 14 (42.4%) | 0.765 |
Neurological symptoms | 0 | 5 (15.2%) | 0.105 |
Renal symptoms | 3 (15%) | 6 (18.2%) | 0.765 |
SARS-CoV-2 test results, n (%) | |||
Positive RT-PCR | 4 (20%) | 8 (24.2%) | 0.721 |
Positive serology | 18 (90%) | 24/31 (77.4%) | 0.250 |
Laboratory confirmed SARS-CoV-2 infection | 18 (90%) | 29 (87.9%) | 1.00 |
Epidemiological link to confirm SARS-CoV-2 infection | 8 (40%) | 12 (36.4%) | 0.95 |
Cardiogical disorders, n (%) | |||
Myocardial dysfunction | 19 (95%) | 0 | N.A. |
Coronary artery abnormalities | 2 (10) | 4 (12.1%) | N.A. |
Coronary artery aneurysm | 0 | 0 | N.A. |
Mitral valve regurgitation | 9 (45%) | 5 (15.2%) | N.A. |
Pericardial effusion | 3 (15%) | 6 (18.2%) | N.A. |
Abnormal ECG | 13 (65%) | 4 (12.1%) | N.A. |
Laboratory test at admission (normal range), median (IQR) | |||
Platelets (150–400 Giga/L) | 237.5 (135.5-329.25) | 252 (208–343) | 0.335 |
WBC count (4.5–11.5 Giga/L) | 13.565 (9.65–17.06) | 11.45 (8.87–17.07) | 0.335 |
Absolute lymphocyte count (0.9-4 Giga/L) | 1.385 (1-2.26) | 1.61 (0.95–2.84) | 0.125 |
C-reactive protein (< 2.2 mg/L) | 188.53 (64.19-232.99) | 133.21 (88.76-205.85) | 0.176 |
PCT (< 0.5 ug/L) | 1.69 (0.86–5.53) | 1.83 (0.51–3.625) | 0.349 |
Interleukin-6 (< 7 ng/L) | 174.1 (102.95-286.45) | 189.15 (68.17–489.3) | 0.005 |
Cardiac TnT (< 10 ng/L) | 26.2 (19.68–88.46) | 21.47 (12.82–36.5) | 0.002 |
Pro-BNP (< 191.1 ng/L) < 191.1 | 9268.875 (2406.22-17237.48)) | 1634.74 (701.21-5085.19) | 0.006 |
Ferritin (13–150 ug/L) | 500.5 (379.05–692.3) | 355.7 (169.47–598.4) | 0.651 |
INR | 1 (0.955–1.11) | 1.04 (0.98–1.11) | 0.309 |
D-dimer (< 0.5 mg FEU/L) | 2.575 (1.53–3.98) | 2.16 (1.4–4.88) | 0.180 |
Albumin (35–52 g/L) | 32 (29-35.75) | 35 (31.75–38.25) | 0.517 |
Urea (1.4–6.8 mmol/L) | 5.15 (3.7–6.73) | 4.2 (3.45-6) | 0.844 |
Creatinine (26–88 umol/L) | 42 (34.5–49) | 44 (32-57.5) | 0.185 |
GPT (< 40 U/L) | 22 (14.25–29.5) | 19.5 (12.25–36.75) | 0.149 |
Bicarbonate (24 mmol/L) | 25.75 (23.57–27.45) | 24.25 (22.6–25.5) | 0.804 |
pH (7.4) | 7.465 (7.45–7.49) | 7.42 (7.39–7.45) | 0.008 |
Clinical outcome, n (%) | |||
Days of pediatric intensive care unit (median) | 3 (15%) | 2 (6.1%) | 0.428 |
Respiratory support | 1 (5%) | 4 (12.1) | 0.721 |
Vasoactive drugs | 11 (55%) | 7 (21.2%) | 0.027 |
Death | 0 | 0 | N/A |